Evonik Industries acquires the company MedPalett AS, with headquarters in Sandnes (Norway), on March 3, 2016. MedPalett AS specializes in food ingredients containing anthocyanins. The acquisition helps Evonik expand the portfolio of its Health Care Business Line in the area of advanced food ingredients. The parties have agreed not to disclose the purchase price.
Anthocyanins are known for their natural antioxidant properties. Numerous international studies suggest broad health-promoting properties including the prevention of cardiovascular disease.
“We are seeing an increase in demand for innovative food ingredients, especially those made from natural substances with scientifically proven benefits, and that’s something we want to be a part of,” says Dr. Reiner Beste, chairman of the Board of Management of Evonik Nutrition & Care GmbH.
MedPalett, which previously belonged to the Norwegian Biolink Group, developed a berry extract from wild Scandinavian
bilberries and black currants from New Zealand that has a particularly high and stable anthocyanin content. The company manufactures the ingredient itself. The berry extract, which is marketed as a dietary supplement under the brand name Medox®, has been available in Scandinavia since the year 2000.
Evonik has distributed the berry extract since 2015 under the name Healthberry™ 865, with exclusive distribution rights in Canada, Brazil, China, Japan, Korea, Australia, New Zealand, and South Africa.
“We have been a partner to the food ingredients industry for decades with our high-purity amino acids. Expanding our portfolio with nutritional solutions which promote health is a logical step in the development of our Health Care business,” says Dr. Jean-Luc Herbeaux, head of the Health Care Business Line at Evonik. For MedPalett, the integration into the Evonik Group primarily means improved access to international markets and higher R&D resources.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around
€4.9 billion in 2015.
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.